Select publications

Publications discussed by Dr Dreicer

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Kirk D, for the Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation? BJU Int 2000;86(Suppl 3):220. Abstract

Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 1997;79:235-46. Abstract

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8. Abstract

Milbank AJ, Dreicer R, Klein EA. Hormonal therapy for prostate cancer: Primum non nocere. Urology 2002;60:738-41. Abstract

Partin AW et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445-51. Abstract

Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. Abstract

Roth BJ et al. Phase I/II trial of bortezomib (PS-341) plus docetaxel in patients with advanced androgen-independent prostate cancer. Proc ASCO 2003;Abstract 1705

Soloway MS. Timing of androgen deprivation for prostate cancer: Benefits versus side effects — a patient physician dialogue. Urology 2002;60:738-41. Abstract

Predicting the risk of progression

Bianco FJ Jr et al. Radical prostatectomy nomograms in black American men: Accuracy and applicability. J Urol 2003;170(1):73-6; discussion 76-7. Abstract

Chan TY et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56(5):823-7. Abstract

Djavan B et al. PSA Progression following radical prostatectomy and radiation therapy: New standards in the new millenium. Eur Urol. 2003;43(1):12-27. Abstract

Graefen M et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 2002;7(4):141-6. Abstract

Han M et al. A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 2000;56(6):994-9. Abstract

Han M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517-23. Abstract

Han M, Partin AW. Nomograms for clinically localized prostate cancer. Part I: Radical prostatectomy. Semin Urol Oncol 2002;20(2):123-30. Abstract

Khan MA, Partin AW. Partin tables: Past and present. BJU Int 2003;92(1):7-11. Abstract

Home

Editor’s Note

Mack Roach III, MD
    - Select publications

Robert Dreicer, MD, FACP
    - Select publications

Leslie R Schover, PhD
    - Select publications

Editor's Office